Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody in Patients With the Metabolic Syndrome PHASE IIa A Single-blinded Placebo-controlled Clinical Trial

NCT01205087 is registered in ClinicalTrials.gov with Hadassah Medical Organization as lead sponsor.

NCT NCT01205087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01205087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Oral Administration of Anti-CD3 Monoclonal Antibody in Patients With the Metabolic Syndrome PHASE IIa A Single-blinded Placebo-controlled Clinical Trial
Lead sponsor
Hadassah Medical Organization
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2010
Completion date
April 30, 2011
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis